EBV-associated colonic B-cell lymphoma following treatment with infliximab for IBD: A new problem?

BMJ Case Reports

Volumn , Issue , 2013, Pages

  Allen, Patrick B ^a   Laing, Georgina ^b   Connolly, Aoife ^b   O'Neill, Ciaran ^c  

^a ULSTER HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c ANTRIM AREA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE;

AGED; ARTICLE; CASE REPORT; COLON CANCER; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; DESCENDING COLON; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY SURGERY; ENTERITIS; EPSTEIN BARR VIRUS INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE PERFORATION; LAPAROTOMY; LARGE CELL LYMPHOMA; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; RECTUM HEMORRHAGE; REMISSION; SIGMOIDOSCOPY; SYMPTOM; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 84886668086     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2013-200423     Document Type: Article

References (20)

1. Lakatos P, Lovasz B, David G, et al. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe. J Crohns Colitis 2012.
2. Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011;106:2146-53.
3. Sokol H, Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 2009;58:1427-36.
4. Beaugerie L, Brousse N, Bouvier A, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25.
5. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
6. Jones J, Loftus E. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis 2007;13:1299-307. (Pubitemid 47597781)
7. Kwon J, Farrell R. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Rev Oncol Hematol 2005;56:169-78. (Pubitemid 41278655)
8. Smith M, Irving P, Marinaki A, et al. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther 2010;32:119-30.
9. Miehsler W, Novacek G, Wenzi H, et al. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis 2010;4:221-56.
10. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5. (Pubitemid 41025906)
11. Armstrong R, West J, Card T. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 2010;105:1604-9.
12. Ljung T, Karlén P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53. (Pubitemid 38662135)
13. Plaza R, Ponferrada A, Benito DM, et al. Plasmablastic lymphoma associated to Crohn's disease and hepatitis C virus chronic infection. J Crohns Colitis 2011;5:628-32.
14. Van Hauwaert V, Meers S, Verhoef G, et al. Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis. J Crohns Colitis 2010;4:683-6.
15. Redmond M, Quinn J, Murphy P, et al. Plasmablastic lymphoma presenting as a paravertebral mass in a patient with Crohn's disease after immunosuppressive therapy. J Clin Pathol 2007;60:80-1. (Pubitemid 46142675)
16. Schwartz LK, Kim MK, Coleman M, et al. Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:1030-4. (Pubitemid 44118850)
17. Podolsky DK, Gonzalez RG, Hasserjian RP. Case records of the Massachusetts General Hospital. Case 8-2006. A 71-year-old woman with Crohn's disease and altered mental status. N Engl J Med 2006;354:1178-84.
18. Losco A, Gianelli U, Cassani B, et al. Epstein-Barr virus-associated lymphoma in Crohn's disease. Inflamm Bowel Dis 2004;10:425-9. (Pubitemid 39029186)
19. Dayharsh G, Loftus E Jr, Sandborn W, et al. Epstein-Barr virus positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002;122:72-7. (Pubitemid 34049196)
20. Vos A, Bakkal N, Minnee R, et al. Risk of malignant lymphoma in patients with inflammatory bowel doseases: a Dutch nationwide study. Inflamm Bowel Dis 2011;17:1837-45.